Grasustek

Grasustek is a product that contains the active ingredient pegfilgrastim, supplied as a solution for subcutaneous injection. It is marketed in the EU and classified as a granulocyte colony‑stimulating factor (G‑CSF) analog. The formulation is intended for administration to support patients undergoing chemotherapy, helping to reduce the risk of neutropenia. Grasustek is administered under the supervision of a qualified healthcare professional and is stored according to the product labeling.

Grasustek is indicated for use in adult patients receiving myelosuppressive chemotherapy to reduce the incidence of febrile neutropenia.

- Prophylaxis of chemotherapy‑induced neutropenia in patients with solid tumors. - Support for patients with hematologic malignancies undergoing high‑dose chemotherapy. - Use when the anticipated risk of neutropenia is ≥20% based on chemotherapy regimen. - Administration as a single dose per chemotherapy cycle, typically 24 hours after chemotherapy completion. - May be considered in patients with prior episodes of neutropenia despite standard G‑CSF therapy.

The safety profile of pegfilgrastim reflects its pharmacologic activity on bone marrow; reported adverse events are categorized as common or serious.

Common: - Bone pain, often in the back, hips, or sternum. - Mild injection‑site reactions such as erythema or swelling. - Fatigue or generalized weakness. - Nausea or mild gastrointestinal discomfort.

Serious: - Splenic rupture or enlargement. - Acute respiratory distress syndrome (ARDS). - Severe allergic reactions, including anaphylaxis. - Capillary leak syndrome.

When prescribing Grasustek, clinicians should evaluate patient history and monitor for conditions that may increase risk of adverse outcomes.

- Avoid use in patients with known hypersensitivity to pegfilgrastim or its excipients. - Use caution in individuals with a history of splenic disorders or abdominal trauma. - Assess renal or hepatic impairment, as clearance may be altered. - Monitor complete blood counts before and after administration to detect unexpected leukocytosis. - Consider dose adjustment or alternative therapy in pregnant or breastfeeding women only if benefits outweigh risks. - Be aware of potential for bone pain; provide appropriate analgesia if needed.

Pegfilgrastim may interact with other medications or biologics; understanding these interactions helps to minimize clinical complications.

Avoid: - Concurrent use with other colony‑stimulating factors (e.g., filgrastim) due to overlapping mechanisms. - Live vaccines administered within 4 weeks of pegfilgrastim, as immune response may be altered.

Use with caution: - Chemotherapeutic agents that cause profound myelosuppression; timing of pegfilgrastim should follow chemotherapy completion. - Corticosteroids may mask bone‑pain symptoms. - Anticoagulants, as severe thrombocytopenia could increase bleeding risk if it occurs. - Immunosuppressive biologics, where combined effects on immune modulation require close monitoring.